Trevena
TRVN
$0.39
Share price
-4.40%
Change (1 day)
-39.85%
Change (1 year)
Categories
P/S ratio for Trevena (TRVN)
P/S ratio as of April 2024 (TTM): 2.23
According to Trevena's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.23371. At the end of 2023 the company had a P/S ratio of 2.58.
P/S ratio history for Trevena from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.58 | |
| 2022 | N/A | -100% |
| 2021 | 169 | 51.49% |
| 2020 | 112 | -95.63% |
| 2019 | > 1000 | 41281.99% |
| 2018 | 6.18 | |
| 2017 | N/A | -100% |
| 2016 | 82.1 | -3.85% |
| 2015 | 85.3 | |
| 2014 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 5.14 | 129.97% | 🇺🇸 USA |
 Merck MRK | 5.53 | 147.50% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Cytokinetics
CYTK | 907 | 40,524.61% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | 22.4 | 902.58% | 🇺🇸 USA |
 Cara Therapeutics
CARA | 1.78 | -20.13% | 🇺🇸 USA |
 Arena Pharmaceuticals
ARNA | N/A | N/A | 🇺🇸 USA |